Last Updated : July 26, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Botox | onabotulinumtoxinA | Migraine, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
Braftovi | encorafenib | Metastatic colorectal cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Braftovi and Mektovi | encorafenib and binimetinib | Advanced Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Brenzys | Etanercept | Rheumatoid arthritis, Ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Breo Ellipta | Fluticasone Furoate and Vilanterol (as trifenatate) | Asthma | List with clinical criteria and/or conditions | Complete | ||
Breo Ellipta | Fluticasone furoate /vilanterol | Chronic Obstructive Pulmonary Disease (COPD) | List with criteria/condition | Complete | ||
Breo Ellipta | fluticasone furoate/vilanterol | COPD | Withdrawn | |||
Breo Ellipta | fluticasone furoate/vilanterol | Asthma | Withdrawn | |||
Breyanzi | lisocabtagene maraleucel | Relapsed or refractory large B-cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Breyanzi | lisocabtagene maraleucel | Relapsed or refractory large B-cell lymphoma | Active | |||
Breztri Aerosphere | budesonide/ glycopyrronium /formoterol fumarate | chronic obstructive pulmonary disease (COPD) | Reimburse with clinical criteria and/or conditions | Complete | ||
Brilinta | Ticagrelor | Acute coronary syndromes | Do not list | Complete | ||
Brilinta | Ticagrelor | Acute Coronary Syndromes | Cancelled | |||
Brilinta | ticagrelor | Prevention of atherothrombotic events with history of myocardial infarction | Reimburse with clinical criteria and/or conditions | Complete | ||
Brineura | cerliponase alfa | Neuronal Ceroid Lipofuscinosis Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Brivlera | Brivaracetam | Epilepsy, partial-onset seizures | Reimburse with clinical criteria and/or conditions | Complete | ||
Brukinsa | zanubrutinib | Mantle cell lymphoma (MCL) | Do not reimburse | Complete | ||
Brukinsa | zanubrutinib | Chronic lymphocytic leukemia /small lymphocytic lymphoma. | Reimburse with clinical criteria and/or conditions | Complete | ||
Brukinsa | zanubrutinib | Relapsed or refractory follicular lymphoma | Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Brukinsa | zanubrutinib | Waldenström’s macroglobulinemia | Reimburse with clinical criteria and/or conditions | Complete | ||
BuTrans | Buprenorphine transdermal patch | Pain, persistent (moderate intensity) | Cancelled | |||
BuTrans | Buprenorphine transdermal patch | Pain, moderate intensity persistent pain | Do not list | Complete | ||
Byetta | Exenatide | Diabetes mellitus, type 2 | Do not list | Complete | ||
Bylvay | odevixibat | Progressive familial intrahepatic cholestasis (PFIC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Bystolic | Nebivolol | Hypertension | Do not list at the submitted price | Complete |